Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2017

Open Access 01-12-2017 | Review article

PACAP38 in human models of primary headaches

Authors: Håkan Ashina, Song Guo, Anne L. H. Vollesen, Messoud Ashina

Published in: The Journal of Headache and Pain | Issue 1/2017

Login to get access

Abstract

Background

To review the role of PACAP38 in human models of primary headaches, discuss possible mechanisms of PACAP38-induced migraine, and outline future directions.

Discussion

Experimental studies have established PACAP38 as a potent pharmacological “trigger” molecule of migraine-like attacks. These studies have also revealed a heterogeneous PACAP38 migraine response in migraine without aura patients. In addition, findings from brain imaging studies have demonstrated neuronal and vascular changes in migraine patients both ictally and interictally after PACAP38 infusion.

Conclusion

Human migraine models have shed light on the importance of PACAP38 in the pathophysiology of primary headaches. These studies have also pointed to the PAC1 receptor and the PACAP38 molecule itself as target sites for drug testing. Future research should seek to understand the mechanisms underlying PACAP38-induced migraine. The results from an ongoing proof of concept randomized clinical trial may reveal the therapeutic potential of anti-PAC1 receptor antibodies for migraine prevention.
Literature
1.
Schytz HW, Hargreaves R, Ashina M (2017) Challenges in developing drugs for primary headaches. Prog Neurobiol 152:70–88CrossRefPubMed
2.
Vollesen ALH, Ashina M (2017) PACAP38: Emerging Drug Target in Migraine and Cluster Headache. Headache 57:Suppl 2:56–63
3.
4.
Sheward WJ, Lutz EM, Copp AJ, Harmar AJ (1998) Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo. Brain Res Dev Brain Res 109:245–253CrossRefPubMed
5.
Miyata A, Jiang L, Dahl RD et al (1990) Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). Biochem Biophys Res Commun 170:643–648CrossRefPubMed
6.
Mulder H, Uddman R, Moller K et al (1994) Pituitary adenylate cyclase activating polypeptide expression in sensory neurons. Neuroscience 63:307–312CrossRefPubMed
7.
Uddman R, Tajti J, Hou M, Sundler F, Edvinsson L (2002) Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2. Cephalalgia 22:112–116CrossRefPubMed
8.
Dun EC, Huang RL, Dun SL et al (1996) Pituitary adenylate cyclase activating polypeptide-immunoreactivity in human spinal cord and dorsal root ganglia. Brain Res 721:233–237CrossRefPubMed
9.
Uddman R, Tajti J, Möller S, Sundler F, Edvinsson L (1999) Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia. Brain Res 826:193–199CrossRefPubMed
10.
Ghatei MA, Takahashi K, Suzuki Y, Gardiner J, Jones PM, Bloom SR (1993) Distribution, molecular characterization of pituitary adenylate cyclase activating polypeptide and its precursor encoding messenger RNA in human and rat tissues. J Endocrinol 136:159–166CrossRefPubMed
11.
Dickson L, Finlayson K (2009) VPAC and PAC receptors: from ligands to function. Pharmacol Ther 121:294–316CrossRefPubMed
12.
13.
Knutsson M, Edvinsson L (2002) Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. Neuroreport 13:507–509CrossRefPubMed
14.
Chan KY, Baun M, De Vries R et al (2011) Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 31:181–189CrossRefPubMed
15.
Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52:269–324PubMed
16.
Ottesen B, Pedersen B, Nielsen J, Dalgaard D, Wagner G, Fahrenkrug J (1987) Vasoactive intestinal polypeptide (VIP) provokes vaginal lubrication in normal women. Peptides 8:797–800CrossRefPubMed
17.
Boni L, Ploug K, Olesen J, Jansen-Olesen I, Gupta S (2009) The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery. Cephalalgia 29:837–847CrossRefPubMed
18.
Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP (2008) Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123:398–410CrossRefPubMedPubMedCentral
19.
Tajti J, Tuka B, Botz B, Helyes Z, Vecsei L (2015) Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. CNS Neurol Disord Drug Targets 14:540–553CrossRefPubMed
20.
Fahrenkrug J, Hannibal J, Tams J, Georg B (2000) Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 20:1205–1214CrossRefPubMed
21.
Akerman S, Goadsby PJ (2015) Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl med 7:308ra157CrossRefPubMed
22.
23.
24.
Birk S, Sitarz JT, Petersen KA et al (2007) The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept 140:185–191CrossRefPubMed
25.
Shayestagul NA, Christensen CE, Amin FM et al (2017) Measurement of blood flow velocity in the middle cerebral artery during spontaneous migraine attacks: a systematic review. Headache 57:852–861CrossRefPubMed
26.
Vollesen AL, Guo S, Ashina M (2017) PACAP38 dose-response pilot study in migraine patients. Cephalalgia 37:391–395CrossRefPubMed
27.
Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629–808
28.
Guo S, Olesen J, Ashina M (2014) Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain 137:2951–2959CrossRefPubMed
29.
Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16–25CrossRefPubMed
30.
Hansen JM, Hauge AW, Olesen J, Ashina M (2010) Calcitonin gene related peptide triggersmigraine-like attacks in patients with migraine with aura. Cephalalgia 30:1179–1186CrossRefPubMed
31.
Thomsen LL, Kruuse C, Iversen HK, Olesen J (1994) A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol 1:73–80CrossRefPubMed
32.
Amin FM, Lundholm E, Hougaard A et al (2014) Measurement precision and biological variation of cranial arteries using automated analysis of 3 T magnetic resonance angiography. J Headache Pain 15:25CrossRefPubMedPubMedCentral
33.
Amin FM, Asghar MS, Guo S et al (2012) Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia 32:140–149CrossRefPubMed
34.
Amin FM, Hougaard A, Schytz HW et al (2014) Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain 137:779–794CrossRefPubMed
35.
Asghar MS, Hansen AE, Kapijimpanga T et al (2010) Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology 75:1520–1526CrossRefPubMed
36.
Grande G, Nilsson E, Edvinsson L Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myography and pressurized cerebral artery method. Cephalalgia 33:152–159
37.
Humphrey PP, Feniuk W (1991) Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 12:444–446CrossRefPubMed
38.
39.
Amin FM, Asghar MS, Ravneberg JW et al (2013) The effect of sumatriptan on cephalic arteries: a 3T MR-angiography study in healthy volunteers. Cephalalgia 33:1009–1016CrossRefPubMed
40.
Asghar MS, Hansen AE, Amin FM et al (2011) Evidence for a vascular factor in migraine. Ann Neurol 69:635–645CrossRefPubMed
41.
Harmar AJ, Arimura A, Gozes I et al (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265–270PubMed
42.
Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28:226–236CrossRefPubMed
43.
Guo S, Vollesen ALH, Hansen YB et al (2017) Part II: biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients. Cephalalgia 37:136–147CrossRefPubMed
44.
Amin FM, Hougaard A, Magon S et al (2016) Change in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study. Neurology 86:180–187CrossRefPubMed
45.
Seeley WW, Menon V, Schatzberg AF et al (2007) Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 27:2349–2356CrossRefPubMedPubMedCentral
46.
Buckner RL, Andrews-Hanna JR, Schacter DL (2008) The brain’s default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 1124:1–38CrossRefPubMed
47.
48.
Peyron R, Laurent B, Garcıa-Larrea L (2000) Functional imaging of brain responses to pain. A review and meta-analysis. Neurophysiol Clin Neurophysiol 30:263–288CrossRef
49.
Guo S, Haulund Vollesen AL, Olesen J, Ashina M (2016) Premonitory and non-headache symptoms induced by CGRP and PACAP38 in migraine patients. Pain 157:2773–2781CrossRefPubMed
50.
Afridi SK, Kaube H, Goadsby PJ (2004) Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110:675–680CrossRefPubMed
51.
52.
Ziegler DK, Hur YM, Bouchard TJ, Hassanein RS, Barter R (1998) Migraine in twins raised together and apart. Headache 38:417–422CrossRefPubMed
53.
Gervil M, Ulrich V, Kyvik KO, Olesen J, Russell MB (1999) Migraine without aura: a population-based twin study. Ann Neurol 46:606–611CrossRefPubMed
54.
Guo S, Vollesen ALH, Hansen RD et al (2017) Part I: pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine. Cephalalgia 37:125–135CrossRefPubMed
55.
Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J (2004) The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24:1352–1358CrossRefPubMed
56.
57.
Lassen LH, Thomsen LL, Olesen J (1995) Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 6:1475–1479CrossRefPubMed
58.
Baun M, Pedersen MHF, Olesen J, Jansen-Olesen I (2012) Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38. Cephalalgia 32:337–345CrossRefPubMed
59.
Bhatt DK, Gupta S, Olesen J, Jansen-Olesen I (2014) PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells. Cephalalgia 34:877–886CrossRefPubMed
60.
Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM (2007) Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130:166–176CrossRefPubMedPubMedCentral
61.
Uddman R, Luts A, Arimura A, Sundler F (1991) Pituitary adenylate cyclase-activating peptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract. Cell Tissue Res 265:197–201
62.
Moller K, Zhang YZ, Håkanson R et al (1993) Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 57:725–732CrossRefPubMed
63.
64.
Edvinsson L, Hara H, Uddman R (1989) Retrograde tracing of nerve fibers to the rat middle cerebral artery with true blue: colocalization with different peptides. J Cereb Blood Flow Metab 9:212–218CrossRefPubMed
65.
Uddman R, Hara H, Edvinsson L (1989) Neuronal pathways to the rat middle meningeal artery revealed by retrograde tracing and immunocytochemistry. J Auton Nerv Syst 26:69–75CrossRefPubMed
66.
Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L (2013) Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain 14:1289–1303CrossRefPubMed
67.
Shioda S, Shuto Y, Somogyvari-Vigh A et al (1997) Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain. Neurosci Res 28:345–354CrossRefPubMed
68.
69.
Jansen-Olesen I, Mortensen A, Edvinsson L (1996) Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 16:310–316CrossRefPubMed
70.
Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J (2001) Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19:369–386CrossRefPubMed
71.
Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J (2002) CGRP may play a causative role in migraine. Cephalalgia 22:54–61CrossRefPubMed
72.
Ingram SL, Williams JT (1996) Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons. J Physiol 492:97–106CrossRefPubMedPubMedCentral
73.
Strassman AM, Raymond SA, Burstein R (1996) Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384:560–564CrossRefPubMed
74.
75.
Banks WA, Uchida D, Arimura A, Somogyvári-Vigh A, Shioda S (1996) Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. Ann N Y Acad Sci 805:270–277CrossRefPubMed
76.
Dogrukol-Ak D, Tore F, Tuncel N (2004) Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 10:1325–1340CrossRefPubMed
77.
Hashimoto H, Shintani N, Baba A (2006) New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor-knockout mice. Ann N Y Acad Sci 1070:75–89CrossRefPubMed
78.
Zhang Y, Malmberg AB, Yaksh TL, Sjölund B, Sundler F, Håkanson R (1997) Capsaicin-evoked release of pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide (CGRP) from rat spinal cord in vivo. Regul Pept 69:83–87CrossRefPubMed
79.
Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129:2787–2789CrossRefPubMed
80.
Maniyar FH, Sprenger T, Monteith T, Schankin C, Goadsby PJ (2014) Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain 137:232–241CrossRefPubMed
81.
Tuka B, Helyes Z, Markovics A et al (2013) Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 33:1085–1095CrossRefPubMed
82.
83.
Jakab B, Reglodi D, Jozsa R et al (2004) Distribution of PACAP-38 in the central nervous system of various species determined by a novel radioimmunoassay. J Biochem Biophys Methods 61:189–198CrossRefPubMed
84.
Hannibal J, Mikkelsen JD, Clausen H, Holst JJ, Wulff BS, Fahrenkrug J (1995) Gene expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat hypothalamus. Regul Pept 55:133–148CrossRefPubMed
85.
Ashina M, Bendtsen L, Jensen R, Schifter S, Jansen-Olesen I, Olesen J (2000) Plasma levels of calcitonin gene-related peptide in chronic tension-type headache. Neurology 55:1335–1340CrossRefPubMed
86.
Stankewitz A, May A (2011) Increased limbic and brainstem activity during migraine attacks following olfactory stimulation. Neurology 77:476–482CrossRefPubMed
87.
Schulte LH, May A (2016) The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 139:1987–1993CrossRefPubMed
88.
Christiansen I, Daugaard D, Lykke Thomsen L, Olesen J (2000) Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency. Eur J Neurol 7:405–411CrossRefPubMed
89.
Cauvin A, Buscail L, Gourlet P et al (1990) The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK. Peptides 11:773–777CrossRefPubMed
90.
Banks WA, Kastin AJ, Komaki G, Arimura A (1993) Pituitary adenylate cyclase activating polypeptide (PACAP) can cross the vascular component of the blood-testis barrier in the mouse. J Androl 14:170–173PubMed
91.
Bourgault S, Vaudry D, Botia B et al (2008) Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 29:919–932CrossRefPubMed
Metadata
Title
PACAP38 in human models of primary headaches
Authors
Håkan Ashina
Song Guo
Anne L. H. Vollesen
Messoud Ashina
Publication date
01-12-2017
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2017
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-017-0821-3

Other articles of this Issue 1/2017

The Journal of Headache and Pain 1/2017 Go to the issue

Research article

Migraine and the risk of post-traumatic stress disorder among a cohort of pregnant women

Review article

Headache attributed to airplane travel: diagnosis, pathophysiology, and treatment – a systematic review

Research article

Disrupted functional connectivity of periaqueductal gray subregions in episodic migraine

Research article

OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study

Research article

Anxiety and depression symptoms and migraine: a symptom-based approach research

Review article

Cardiac cephalalgia: one case with cortical hypoperfusion in headaches and literature review